113975-32-9

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-IODO-PYRIDIN-3-YL)-2,2-DIMETHYL-PROPIONAMIDE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its iodine and pyridine groups contribute to its reactivity and potential as a building block in the development of new drugs.
Used in Agricultural Chemicals:
In the agricultural sector, N-(4-IODO-PYRIDIN-3-YL)-2,2-DIMETHYL-PROPIONAMIDE is used as a component in the formulation of agrochemicals. Its chemical structure may provide specific properties that are beneficial for the development of effective and targeted pest control products.
Used in Materials Science:
N-(4-IODO-PYRIDIN-3-YL)-2,2-DIMETHYL-PROPIONAMIDE is used as a key component in the synthesis of advanced materials. Its unique structure may contribute to the development of new materials with improved properties, such as enhanced stability or reactivity, for use in various applications.

InChI:InChI=1/C10H13IN2O/c1-10(2,3)9(14)13-8-6-12-5-4-7(8)11/h4-6H,1-3H3,(H,13,14)

Upstream product

• 70298-88-3 N-(pyridin-3-yl)pivalamide 
• 20485-44-3 2,3-dimethyl-2,3-diaminobutane 
• 13444-90-1 Nitryl chloride 
• 462-08-8 pyridin-3-ylamine 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 131653-66-2 2-[3-(2,2-dimethylpropanoylamino)pyridin-4-yl]-N,N-diisopropylbenzamide 
• 131653-67-3 Diethyl-carbamic acid 2-[3-(2,2-dimethyl-propionylamino)-pyridin-4-yl]-phenyl ester 
• 131653-68-4 Diethyl-carbamic acid 6-[3-(2,2-dimethyl-propionylamino)-pyridin-4-yl]-2,3-dimethoxy-phenyl ester 
• 105752-11-2 4-iodopyridin-3-amine 
• 131653-64-0 2,2-dimethyl-N-(4-phenyl-3-pyridyl)propanamide 
• 1395412-56-2 N-(2-chloro-5-fluoro-[3,4']bipyridinyl-3'-yl)-N-methyl-3,5-bis-trifluoromethyl-benzamide 
• 1395412-94-8 N-{4-[2-(2-hydroxy-ethyl)-phenyl]-pyridin-3-yl}-N-methyl-3,5-bis-trifluoromethyl-benzamide 
• 1395414-19-3 N-methyl-N-[4-(4-methyl-2H-pyrazol-3-yl)-pyridin-3-yl]-3,5-bis-trifluoromethyl-benzamide 
• 1395415-54-9 N-(4-iodo-pyridin-3-yl)-N-methyl-3,5-bis-trifluoromethyl-benzamide 
• 1291057-14-1 (E)-4-iodo-3-phenylazopyridine 
• 1418921-50-2 (Z)-4-iodo-3-phenylazopyridine 
• 113975-42-1 2-tert-butyl-1H-pyrrolo<2,3-c>pyridine 
• 131653-65-1 2,2-dimethyl-N-(4-(2-methoxyphenyl)-3-pyridyl)propanamide 
• 146140-96-7 2,2-dimethyl-N-(4-(2-fluorophenyl)-3-pyridyl)propanamide 

Relevant academic research and scientific papers

3-AMINO-PYRIDINES AS GPBAR1 AGONISTS

This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes

3-AMINO-PYRIDINES AS GPBAR1 AGONISTS

This invention relates to novel 3-aminopyridines of the formula (I) wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

The first porous MOF with photoswitchable linker molecules

We synthesized a porous twofold interpenetrated MOF [Zn2(NDC) 2(1)] (coined CAU-5) using 3-azo-phenyl-4,4′-bipyridine (1), 2,6-naphthalenedicarboxylic acid, and Zn(NO3)2· 6H2O. The azo-functionality protrudes into the pores, and can be switched, by irradiation with UV light (365 nm), from the thermodynamically stable trans-isomer to the cis-isomer. Back-switching was achieved thermally and with an irradiation wavelength of λmax = 440 nm.

AZA-BETA-CARBOLINES AND METHODS OF USING SAME

Provided are compounds having the general structure according to Formula (I): Further provided are pharmaceutical compositions comprising these compounds. The invention still further provides methods of treating alcoholism, methods of reducing alcohol intake, methods of treating anhedonia, and methods of treating anxiety using theses compounds or the compositions containing them.

IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT' OF CANCER

The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or rnethylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo;, R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.

TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS

The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

Nonsteroidal glucocorticoid agonists: Tetrahydronaphthalenes with alternative steroidal A-ring mimetics possessing dissociated (Transrepression/Transactivation) efficacy selectivity

The synthesis and biological activity of tetrahydronaphthalene derivatives coupled to various heterocycles are described. These compounds are potent glucocorticoid receptor agonists with efficacy selectivity in an NFκB glucocorticoid receptor (GR) agonist assay (representing transrepression effects) over an MMTV GR agonist assay (representing transactivation effects). Quinolones, indoles, and C- and N-linked quinolines are some of the heterocycles that provide efficacy selectivity. For example, the isoquinoline 49D1E2 has NFκB agonism with pIC50 of 8.66 (89%) and reduced efficacy in MMTV agonism (6%), and the quinoline 55D1E1 has NFκB agonism with pIC 50 of 9.30 (101%) and reduced efficacy in MMTV agonism with pEC 50 of 8.02 (47%). A description of how a compound from each class is modeled in the active site of the receptor is given.

Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands

The invention relates to tetrahydronaphthyridine derivatives having formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said tetrahydronaphthyridine derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

Synthesis of optically active ring-A substituted tryptophans as IDO inhibitors

The first synthesis of optically active 7-methoxy-d-tryptophan as well as other ring-A substituted tryptophans is described.

Compounds and their use

This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.